News – Page 6 – Alligator Bioscience

2021-03-11

Mitazalimab synergizes with chemotherapy – Alligator Bioscience presents new preclinical data at AACR

Lund, Sweden, March 11, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that an abstract for a poster presentation at ...

2021-02-26

Regulatory

Change in number of shares and votes in Alligator Bioscience AB

During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...

2021-02-26

Regulatory

Alligator Bioscience AB: Year-end Report January-December 2020

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...

2021-02-23

Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA)

Last day of trading in BTA in Alligator Bioscience AB ("Alligator" or the “Company") will be Friday February 26, 2021 and stop d ...

2021-01-27

Regulatory

Alligator Bioscience’s rights issue oversubscribed

Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareh ...

2021-01-21

Larger shareholder and board member transfer subscription rights free of charge to qualified investors

The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the autho ...

2021-01-15

Alligator Bioscience appoints Chief Scientific Officer

Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark ...

2021-01-11

The subscription period in Alligator Bioscience’s rights issue commences today

Today is the first day of the subscription period in Alligator Bioscience AB (publ)’s (“Alligator” or the “Company”) rights issue of shares ...